Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Information provided by (Responsible Party):
Daewoong Pharmaceutical Co. LTD. Identifier:
First received: July 6, 2012
Last updated: August 20, 2013
Last verified: August 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):